The Medical Letter on Drugs and Therapeutics
Mitomycin Solution (Mitosol) for Glaucoma Surgery
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A topical formulation of the antimetabolite mitomycin (Mitosol – Mobius Therapeutics) has been approved by the FDA for adjunctive use in glaucoma surgery to reduce scarring. Compounding pharmacies have supplied the drug off-label for this purpose for many years.

MECHANISM OF ACTION — Mitomycin inhibits DNA synthesis and, at high concentrations, suppresses cellular RNA and protein synthesis. In glaucoma surgery, it reduces scarring through an inhibitory effect on subconjunctival fibroblasts and vascular endothelial cells.

SURGICAL TREATMENT OF GLAUCOMA — Surgical treatment of glaucoma is usually reserved for patients who have not responded to treatment with ophthalmic drugs1 or to laser therapy. The type of surgical procedure for which Mitosol is approved, ab externo trabeculectomy, removes part of the trabecular meshwork and creates a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Mitomycin Solution (Mitosol) for Glaucoma Surgery
Article code: 1412c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian